Scancell (LON:SCLP) Trading 7% Higher Following Insider Buying Activity

Shares of Scancell Holdings plc (LON:SCLP) were up 7% on Wednesday following insider buying activity. The company traded as high as GBX 10.43 ($0.14) and last traded at GBX 9.90 ($0.13). Approximately 1,065,551 shares changed hands during trading, an increase of 21% from the average daily volume of 878,498 shares. The stock had previously closed at GBX 9.25 ($0.12).

Specifically, insider Martin Diggle acquired 44,944 shares of Scancell stock in a transaction that occurred on Tuesday, May 20th. The shares were acquired at an average cost of GBX 9 ($0.12) per share, with a total value of £4,044.96 ($5,424.38).

Scancell Stock Up 7.0%

The firm has a 50 day moving average of GBX 9.35 and a two-hundred day moving average of GBX 10.24. The firm has a market capitalization of £102.54 million, a price-to-earnings ratio of -15.18 and a beta of 0.35. The company has a quick ratio of 13.01, a current ratio of 3.42 and a debt-to-equity ratio of -566.79.

Scancell Company Profile

Scancell (LSE:SCLP) is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers.

Scancell has developed a pipeline of ‘off-the-shelf’ vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.